Key Points
- Director Luciano Santel sold 2,023 Stevanato Group shares at an average price of €20.09, generating €40,642.07. The sale covered tax-withholding obligations tied to vested equity awards and reduced his holdings by 29.92% to 4,739 shares.
- Stevanato Group shares opened at €20.65, versus a 12-month range of €12.89 to €28.00, with a market capitalization of approximately $6.25 billion and a P/E ratio of 36.87.
- Analyst sentiment remains positive, with the stock holding an average “Buy” rating; several institutional investors also increased their positions during the recent quarters.
Stevanato Group S.p.A. (NYSE:STVN - Get Free Report) Director Luciano Santel sold 2,023 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of €20.09, for a total transaction of €40,642.07. Following the completion of the sale, the director owned 4,739 shares in the company, valued at €95,206.51. The trade was a 29.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Stevanato Group Stock Performance
Shares of STVN stock opened at €20.65 on Tuesday. The business has a 50 day simple moving average of €18.84 and a 200 day simple moving average of €16.98. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08. The firm has a market capitalization of $6.25 billion, a price-to-earnings ratio of 36.87, a price-to-earnings-growth ratio of 1.70 and a beta of 0.77. Stevanato Group S.p.A. has a 12-month low of €12.89 and a 12-month high of €28.00.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on the stock. Weiss Ratings raised shares of Stevanato Group from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, July 16th. TD Cowen raised shares of Stevanato Group to a "strong-buy" rating in a research note on Wednesday, June 17th. Finally, Wolfe Research began coverage on shares of Stevanato Group in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $21.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy".
View Our Latest Report on Stevanato Group
Hedge Funds Weigh In On Stevanato Group
Several large investors have recently made changes to their positions in the business. Handelsbanken Fonder AB grew its stake in shares of Stevanato Group by 26.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 30,600 shares of the company's stock worth $553,000 after purchasing an additional 6,400 shares during the last quarter. First Bank & Trust lifted its stake in Stevanato Group by 3.4% during the second quarter. First Bank & Trust now owns 18,417 shares of the company's stock valued at $333,000 after purchasing an additional 603 shares during the last quarter. Cooper Investors PTY Ltd. boosted its holdings in Stevanato Group by 4.4% during the second quarter. Cooper Investors PTY Ltd. now owns 668,494 shares of the company's stock worth $12,080,000 after buying an additional 28,265 shares in the last quarter. Confluence Investment Management LLC bought a new stake in Stevanato Group during the second quarter worth approximately $6,062,000. Finally, Glenmede Trust Co. NA grew its position in Stevanato Group by 29.5% in the first quarter. Glenmede Trust Co. NA now owns 38,461 shares of the company's stock worth $529,000 after buying an additional 8,770 shares during the last quarter.
About Stevanato Group
(
Get Free Report)
Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.
In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
